Rosetta Genomics Ltd.
ROSG
ROSG was delisted on the 21st of May, 2018.
10 hedge funds and large institutions have $316K invested in Rosetta Genomics Ltd. in 2013 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
5% more call options, than puts
Call options by funds: $64K | Put options by funds: $61K
0% more funds holding
Funds holding: 10 → 10 (0)
18% less capital invested
Capital invested by funds: $387K → $316K (-$71.3K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
+$46.3K |
| 2 |
Citigroup
New York
|
+$14.5K |
| 3 |
U
UBS
Zurich,
Switzerland
|
+$10.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$49K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$10.1K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
-$6.78K |
| 4 |
Millennium Management
New York
|
-$3.37K |
| 5 |
AIG
American International Group
New York
|
-$2.19K |
ROSG Hedge Fund Activity: Q3 2013 in Review
10 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics Ltd. (ROSG) for Q3 2013, worth a combined $316K — down 18% from $387K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ROSG positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Nine Chapters Capital Management, opening a new position worth an estimated $46.3K. The largest seller was Citadel Advisors, exiting entirely with an estimated $49K sold.
- 10 institutional investors held Rosetta Genomics Ltd. (ROSG) as of Q3 2013, unchanged from Q2 2013.
- Funds reported $316K of Rosetta Genomics Ltd. stock for Q3 2013, down 18% quarter-over-quarter.
- 2 funds opened new Rosetta Genomics Ltd. positions in Q3 2013 and 1 closed out, a net change of +1 holder.
- The largest Rosetta Genomics Ltd. buyer in Q3 2013 was Nine Chapters Capital Management, an estimated $46.3K added.
- The largest Rosetta Genomics Ltd. seller in Q3 2013 was Citadel Advisors, an estimated $49K sold.
Based on aggregated 13F filings for Q3 2013.